| Name | Title | Contact Details |
|---|
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
RUCDR Infinite Biologics Becomes Infinity BiologiX IBX will continue to advance RUCDR`s founding mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. IBX will continue to collaborate with – and provide services to – researchers in both the public and private sectors globally, including innovative and market-disrupting sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas.
CG Pharmaceuitcals is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delaware BioScience Association has a broad-based membership including pharmaceutical, biotechnology, medical devices, analytical equipment and agricultural products; as well as representatives from academia, medical research, workforce training and other supporting organizations (financial, legal, marketing, consulting, engineering and construction, etc.) that serve the bioscience community. Delaware Bio is focused on being a unified voice for Delaware and the region`s bioscience community to accelerate the growth of human, animal, plant, and industrial biosciences.
Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.